Serotonin and norepinephrine reuptake inhibitors association with dry mouth in a hospital population.

This article investigates the association between serotonin-norepinephrine reuptake inhibitors (SNRIs) and xerostomia (dry mouth) in a large hospital population using data from the University of Florida Health Center between 2015 and 2022. The study found that patients taking SNRIs were nearly six times more likely to develop dry mouth compared to those not on these medications, with odds ratios consistently elevated across sexes and age groups. Among individual SNRIs, milnacipran showed the highest association with dry mouth, followed by duloxetine, venlafaxine, and desvenlafaxine. The findings highlight the importance for medical and dental professionals to recognize the xerogenic effects of SNRIs, as dry mouth can significantly impact patients' oral health and quality of life.